US health agency approves Alzheimer's drug Leqembi developed for patients in earliest stages of mind-wasting disease
Leqembi and Aduhelm, which were jointly developed by Japan's Eisai and Biogen of US"represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease," says Food and Drug Administration.
The US Food and Drug Administration [FDA] has approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease. It was granted despite the fact that trial results showed the monoclonal antibody treatment carries risks of brain swelling and bleeding.
Leqembi and Aduhelm, which were jointly developed by Japan's Eisai and Biogen of the United States, "represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease," the FDA said in a statement.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Leqembi, Alzheimer's drug that modestly slows diseaseALZHEIMER'S DRUG: The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease's underlying biology. MORE:
Read more »
Second Alzheimer’s treatment showing modest benefits for patients approved by FDAThe FDA has granted accelerated approval to a second Alzheimer’s drug that trial data show offers modest benefits to patients.
Read more »
New Alzheimer’s Drug Approved by FDA, Promises to Slow DiseaseBreaking: A new Alzheimer's drug has been cleared for use in the U.S. Doctors say it could transform the way the disease is treated.
Read more »
FDA Approves Alzheimer's Drug That Modestly Slows DiseaseThe drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s.
Read more »
FDA approves new Alzheimer's drug lecanemab that appears to slow the memory-robbing diseaseFederal drug regulators on Friday approved lecanemab, sold under the brand name Leqembi, an Alzheimer’s drug that appears to slow the disease.
Read more »
US health officials approve closely watched Alzheimer’s drugJUST IN: U.S. health officials on Friday approved a closely watched Alzheimer’s drug that modestly slows the brain-robbing disease, albeit with potential safety risks that patients and their doctors will have to carefully weigh.
Read more »